Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Cancer Vaccines01:30

Cancer Vaccines

330
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
330
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

835
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
835
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitis.

JHEP reports : innovation in hepatology·2026
Same author

Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis.

American journal of respiratory cell and molecular biology·2025
Same author

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.

Journal for immunotherapy of cancer·2025
Same author

Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.

JAMA network open·2025
Same author

[The toxicity pathway, an innovation for managing the toxicity of cancer treatments].

Soins; la revue de reference infirmiere·2025
Same author

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

Related Experiment Video

Updated: May 30, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

1.9K

Immuno-oncology in the daily practice.

Ariane Laparra1

  • 1Gustave Roussy Departement Interdisciplinaire de Soins de Support aux Patients en Onco-hematologie, Villejuif, France.

Current Opinion in Oncology
|January 27, 2025
PubMed
Summary

A new patient care pathway aids early detection and management of immune-related adverse events (irAE) from immune checkpoint inhibitors (ICI). This approach improves patient quality of life and treatment compliance while reducing severe toxicities.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K

Related Experiment Videos

Last Updated: May 30, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

1.9K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Pathway Development

Background:

  • Immune checkpoint inhibitors (ICI) are widely used in oncology but can cause severe immune-related adverse events (irAE).
  • The expanding use of ICI in early-stage cancer and combination therapies complicates toxicity management.
  • Identifying patients at risk for severe ICI-related toxicities remains challenging in routine practice.

Purpose of the Study:

  • To develop and evaluate a novel patient care pathway for managing ICI-induced toxicities.
  • To enable early detection and intervention for immune-related adverse events.
  • To improve patient quality of life and adherence to cancer treatment.

Main Methods:

  • Implementation of a dedicated daily toxicity day hospital for patient evaluation.
  • Establishment of an iTox multidisciplinary board for expert consultation.
  • Utilization of a pharmacovigilance database and a translational research program.

Main Results:

  • The toxicity day hospital facilitated early identification of adverse events and their attribution to anticancer treatment.
  • The pathway enabled timely management of patients experiencing early-stage toxicities.
  • This structured approach aims to enhance patient care and treatment outcomes.

Conclusions:

  • A novel care pathway integrating clinical evaluation, a specialized day hospital, a multidisciplinary board, and pharmacovigilance has been presented.
  • This pathway supports early detection and management of immune-related adverse events, improving patient quality of life.
  • The developed pathway aims to optimize the benefit-risk balance of immunotherapy in oncology.